Protara Therapeutics, Inc. (FRA:1KPA)

Germany flag Germany · Delayed Price · Currency is EUR
6.00
+0.45 (8.11%)
At close: Feb 20, 2026
Market Cap311.12M +34.1%
Revenue (ttm)n/a
Net Income-45.09M
EPS-1.18
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume5
Open6.00
Previous Close5.55
Day's Range6.00 - 6.00
52-Week Range2.26 - 6.50
Betan/a
RSI68.14
Earnings DateMar 9, 2026

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Jesse Shefferman
Employees 31
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1KPA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements